Gesynta Pharma raised $29M in a Series B funding round led by Innovestor Life Science to advance its non-hormonal endometriosis treatment.
Amount Raised
$29 Million
Round Type
Series B
StockholmBiotechnologyHealth CareInvestors
Description
Gesynta Pharma has secured SEK 304 million ($29 million) in Series B funding to support a Phase II clinical trial of its drug candidate, vipoglanstat. The funding will help advance the development of breakthrough treatments for endometriosis, addressing severe pain and symptoms faced by millions of women.
Quick answer
Gesynta Pharma raised $29 Million in a Series B round, dated January 20, 2025. Investors: Stephen Industries, Catalyze Capital, Hadean Ventures, Industrifonden, Linc, Foreground Capital, Amboy Street Ventures and Innovestor Life Science. Gesynta Pharma is based in Stockholm, Stockholm County, Sweden.
- How much did Gesynta Pharma raise?
- Gesynta Pharma raised $29 Million in a Series B round on January 20, 2025.
- Who invested in Gesynta Pharma?
- Stephen Industries, Catalyze Capital, Hadean Ventures, Industrifonden, Linc, Foreground Capital, Amboy Street Ventures and Innovestor Life Science are named as investors in this round.
- What does Gesynta Pharma do?
- Gesynta Pharma is a Swedish biotech company focused on developing innovative treatments for endometriosis.
- Where is Gesynta Pharma based and how big is it?
- Gesynta Pharma is based in Stockholm, Stockholm County, Sweden.
- Who are the decision-makers at Gesynta Pharma?
- Fundz holds 1 contact at Gesynta Pharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Gesynta Pharma that raised within 45 days of this round, from Fundz verified event records.
- Reveleum raised an undisclosed amount on March 6, 2025.
- hema.to raised $3.8M (Seed) on March 6, 2025.
- HelloBetter raised $6.4M (Funding Round) on March 5, 2025.
- TRIMTECH Therapeutics raised $31M (Seed) on March 5, 2025.
- Epoch Biodesign raised $18M (Series A) on March 5, 2025.
- Garuda Therapeutics raised $50M (Series A) on March 5, 2025.
Who to call at Gesynta Pharma, and when
A new round usually means Gesynta Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Gesynta Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gesynta Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gesynta Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gesynta Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGesynta Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.